ProKidney Corp.
PROKHealthcare|Biotechnology|US
$1.14
+0.07 (+7.04%)
DCF Value
$0.86
Tangible Book / Share
$1.19
Cash / Share
$0.97
About
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Stock Price
-59.4%(1Y)
1M
-31.3%
3M
-30.5%
6M
-38.7%
YTD
-49.1%
1Y
-57.8%
3Y
-31.9%
5Y
-88.5%
Pipeline Summary
10 total trials2
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
By Invitation: 1Terminated: 2Completed: 4Recruiting: 1Withdrawn: 1Active: 1
Active Trials (2)
A Long-Term Follow-Up Study of Participants Exposed to REACT
NCT05918523Diabetic Kidney Disease
Recruiting
Enrollment: 80 participants
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770Type 2 Diabetes Mellitus
Phase 3Active
Enrollment: 685 participants
Key Facts
Market Cap$383.3M
Employees231 (+13% YoY)
CEOBruce Culleton
IPO DateJun 30, 2021
Beta1.90
52-Week Range$0.87 – $2.95
Avg Volume1,338,085
ExchangeNASDAQ
Websiteprokidney.com
Ownership
Float73.4%
Shares Outstanding148.2M
Recent Insider Trades
Culleton BruceAWARD
Nov 2, 2026500,000 shares @ $1.69
Weber Darin J.CONVERSION
Oct 28, 2026200,000 shares
Weber Darin J.CONVERSION
Oct 28, 2026200,000 shares
Weber Darin J.CONVERSION
Oct 28, 2026200,000 shares
Pereira Brian JGSELL
Aug 18, 2026229,338 shares @ $1.37
Peers
Recent News
ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500
Oct 28, 2026 · marketbeat.com
ProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease Transcript
Oct 27, 2026 · seekingalpha.com
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update
Oct 22, 2026 · globenewswire.com
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026
Oct 22, 2026 · globenewswire.com
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026
Oct 2, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:29 AM